Highly stable and immunogenic CMV T cell vaccine candidate developed using a synthetic MVA platform

Highly stable and immunogenic CMV T cell vaccine candidate developed using a synthetic MVA platform

Abstract Human cytomegalovirus (CMV) is the most common infectious cause of complications post-transplantation, while a CMV vaccine for transplant recipients has yet to be licensed. Triplex, a multiantigen Modified Vaccinia Ankara (MVA)-vectored CMV vaccine candidate based on the immunodominant anti...

Full description

Bibliographic Details
Main Authors: Marcal Yll-Pico, Yoonsuh Park, Joy Martinez, Angelina Iniguez, Mindy Kha, Taehyun Kim, Leonard Medrano, Vu H. Nguyen, Teodora Kaltcheva, Shannon Dempsey, Flavia Chiuppesi, Felix Wussow, Don J. Diamond
Format: Article
Language:English
Published: Nature Portfolio 2024-03-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-024-00859-3

Internet

https://doi.org/10.1038/s41541-024-00859-3

Similar Items